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Abstract
Finasteride has been used extensively until now as a relative efficient therapeutic option for male androgenic alopecia and
benign prostatic hyperplasia. Unfortunately, over time several concerns appeared regarding the frequency and magnitude of
adverse effects, which in some cases have been even irreversible. Herein we review the recent literature on this topic, trying
to clarify the current safety profile of Finasteride for these two therapeutic indications. We concluded that Finasteride could
be retained as a therapeutic approach for male androgenic alopecia, based on two important reasons. First, a synergistic
action between a partial inhibitor of 5α-reductase (Finasteride) and another compound (like Minoxidil) are preferable to a
complete suppression of 5α-reductase (see Dutasteride), in order to preserve the important physiological roles of
dihydrotestosterone. Second, Finasteride side effects can currently be addressed in part prior to the onset of the therapy, by
using information about the patient such as hand preference and sexual orientation to predict the risk of adverse effects.

Rezumat
Finasterida a fost utilizată pe scară largă până acum pentru alopecia androgenică masculină și hiperplazia benignă de prostată,
fiind o opțiune terapeutică relativ eficientă. Cu timpul însă au apărut tot mai multe preocupări legate de frecvența și
amploarea efectelor adverse, care au fost chiar ireversibile în unele cazuri. Acest articol prezintă o revizuire a literaturii de
specialitate pe această temă cu scopul de a clarifica profilul de siguranță al Finasteridei pentru cele două recomandări
terapeutice. Concluzia este că Finasterida ar putea fi menținută ca și soluție terapeutică pentru alopecia androgenică
masculină, din două motive importante. Primul aspect vizează menținerea rolurilor fiziologice specifice
dihidrotestosteronului, pentru care ar fi de preferat o acțiune sinergică între un inhibitor parțial de 5α-reductază (Finasterida)
și un alt compus precum Minoxidil, față de o suprimare completă a 5α-reductazei (specifică Dutasteridei). Cel de-al doilea
element este legat de reacțiile adverse ale Finasteridei care pot fi avute în vedere chiar și înainte de începerea tratamentului,
caracteristici individuale precum mâna dominantă și orientarea sexuală ale pacientului fiind corelate cu riscul și frecvența
efectelor adverse.
Keywords: finasteride, safety profile, androgenic alopecia, benign prostatic hyperplasia

Introduction

demonstrated through laboratory tests assessing
cerebrospinal fluid and plasma in populations of
men receiving Finasteride [4, 15]. However, recent
studies suggest that Finasteride side effects seem to
be encountered only in a subset of men [7, 16], with
the aggregation of Finasteride adverse effects
apparently related to lateralization processes of the
brain [24, 25]. As a consequence, Finasteride use and
monitoring should take into consideration not only the
general pharmacological properties (pharmacokinetics
and pharmacodynamics) of the drug, but also specific
patient characteristics that are linked to lateralization

Male androgenic alopecia and benign prostatic hyperplasia are relatively common conditions encountered
in elderly male subjects. Their occurrence and
progression are partly supported by the androgenic
action of male sex hormone, dihydrotestosterone
(DHTT). Consequently, several drugs like Finasteride
and Dutasteride that interfere with DHTT synthesis
have been evaluated and implemented as therapeutic
solutions to ameliorate these two conditions [3, 17].
The pharmacologic action of Finasteride (especially
its efficacy in decreasing levels of DHTT) has been
660
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process of the brain such as hand preference and
sexual orientation.
Indeed, recent data suggest that hand preference
(left or right) and sexual orientation may be associated
with the occurrence and severity of Finasteride adverse
effects [24, 25]. In such predisposed men, Finasteride
administration is relatively difficult to manage due to
the variety and magnitude of adverse effects, (including
but not limited to severe depression and sexual
dysfunctions associated with suicidal thoughts) as
well as their indefinite and irreversible persistence even
after cessation of pharmacological action (commonly
referred to as post-finasteride syndrome) [5, 14, 15, 36].
This paper presents the pharmacological profile of
Finasteride and the corresponding neurobiological
substrate able to explain the occurrence of various
Finasteride side effects among different populations
of patients. Such information could help provide the
basis for reconsidering the therapeutic safety profile
of Finasteride in the treatment of male androgenic
alopecia and benign prostatic hyperplasia.

P450 3A4 enzyme subfamily. The corresponding
metabolites possess no more than 20% inhibitory
activity for 5α-reductase comparable to Finasteride
action. Oral administration of Finasteride leads to
its excretion in urine as metabolites (about 39%)
and through faeces (57%, in part unmetabolized).
The mean terminal half-life of finasteride in men
between 45 - 60 years is approximately 6 hours,
though longer in men over 70 years (about 8 hours)
[44].
Finasteride administration produces a relatively rapid
decrease of serum DHTT concentration within 6 - 8
hours, which persists over the 24-hour dosing interval,
or longer for repeated administration. Daily dosing
of finasteride has been shown to suppress serum
DHTT concentration by approximately 65% for a 1 mg
tablet, and 70% for 5 mg. Compared to baseline, the
mean circulating levels of testosterone and estradiol
increase up to 15%, remaining however for most
subjects within the physiologic range. In a similar
manner, the luteinizing hormone (LH) and follicle
stimulating hormone (FSH) increase during Finasteride
administration by about 10%, without exceeding
the physiological level. Thus the hypothalamicpituitary-testicular axis is not affected. No effect
has been reported on thyroid-stimulating hormone,
cortisol, prolactin, plasma lipid profile or bone
mineral density [1, 36].
Finasteride side effects are the consequence of its
direct actions on the brain and peripheral organs
(nausea, vomiting, allergies, etc.), and due to indirect
actions of the drug through dihydrotestosterone and
possible GABA receptors [36]. The most frequent
adverse effects are represented by mental (depression,
suicidal ideations, anhedonia, lack of mental
concentration, etc.) and sexual (impotence, erectile
dysfunction, decreased libido, ejaculation disorders)
impairments. Other adverse effects are also possible:
insomnia, gynecomastia, chronic fatigue, elevated
body mass index, pruritus, rash, urticaria, angioedema,
gingival hypertrophy, etc. (Table I) [21, 30].
Finasteride also seems to change tolerance to ethanol
in many individuals, with former users of finasteride
reporting a decreased tolerance to alcohol [14, 46].
Finally, studies have noted several concerns related
to association or even possible causal relationship
between finasteride administration and high-grade
prostate cancers, or male breast cancer [19, 39].

Pharmacological profile of Finasteride
Finasteride is a partial inhibitor (only type II) of 5αreductase enzyme, which converts intracellular
testosterone to dihydrotestosterone. This enzyme is
encountered in the sebaceous glands and liver (type I
isoenzyme), and also in prostate, seminal vesicles, and
hair follicles (type II isoenzyme). After Finasteride
administration, the serum DHTT concentration
decreases up to 70%, indicating that the type II
isoenzyme generates about two-thirds of the circulating
DHTT, whereas the type I isoenzyme is responsible
for only one-third of the circulating DHTT [31].
In men with male androgenetic alopecia there are
high amounts of DHTT and also miniaturized hair
follicles in the balding scalp, compared with the
hairy scalp. By reducing DHTT, Finasteride interrupts
an important factor implied in the occurrence of
androgenetic alopecia, which is considered a genetically
predisposed condition. In patients with benign
prostatic hyperplasia, the prostate volume decreases
during Finasteride administration by approximately
20%, returning often to the baseline value about three
months after discontinuation of therapy [22, 35].
Finasteride absorption is not affected by food,
presenting a bioavailability around 65%. The maximum
plasmatic concentration is reached about 1 to 2
hours after administration, ranging between 4.9 13.7 ng/mL for 1 mg/day, and between 27 - 49 ng/mL
for 5 mg/day. After successive doses, there is a
slow accumulation phase for Finasteride, with 90%
of the circulating drug bound to plasma proteins.
Finasteride crosses the blood-brain barrier, a property
that explains many Finasteride side effects such as
mental and sexual impairments. It is extensively
metabolized by the liver, especially through cytochrome

Therapeutic window and therapeutic opportunity
of Finasteride
General data regarding Finasteride administration
Finasteride was introduced primarily as a therapeutic
solution for benign prostatic hyperplasia (5 mg
daily), ameliorating specific symptoms such as night
time urination, decreased flow, prolonged initiation,
etc. [40].
661
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Table I
Finasteride adverse effects (administration: four months or more) [21, 36]
Adverse effects
Depression
Anhedonia
Lack of mental concentration
Suicidal ideations
Impotence
Decreased Libido
Ejaculation Disorder
Gynecomastia
Rash
Pruritus
Gingival hypertrophy

Finasteride, 1 mg (%)

Placebo (%)

Finasteride, 5 mg (%)

Placebo (%)

11.76
21.56
17.64
5.88
7.84
16.66
6.86
4.90
2.94
3.92
1.96

3.92
4.90
8.82
0
1.96
2.94
0.0
0
0.98
0.98
0

7.44
19.14
20.21
3.19
9.57
22.34
8.51
6.38
4.25
3.19
1.06

3.19
5.31
11.07
1.06
2.12
5.31
1.06
1.06
1.06
2.12
0

After five years, Finasteride was also approved and
introduced for the therapeutic management of male
androgenic alopecia (at a dose of 1 mg/day) due to
its effect of improving hair stretch by up to 20 30% [8].
These therapeutic effects are usually obtained six
months or more after finasteride administration,
being maintained only so long as the drug is
administered [35]. Such prolonged administration
increases the therapeutic benefits of the drug, but
unfortunately also the frequency and magnitude of
adverse effects [36]. Some adverse effects were
noted from the drug’s outset during preclinical
studies, while others were noted later (during the
post-market experience) [46].
A comprehensive and historically accurate approach
has revealed two distinct findings. First, Finasteride
side effects are encountered not only during
Finasteride administration but also after discontinuation,
known as the post-Finasteride syndrome [36].
Second, it has been observed that some men
tolerate Finasteride quite well, with only a subgroup of patients developing notable and eventually
irreversible adverse effects (severe depression, sexual
dysfunctions, suicidal thoughts, etc.), requiring
drug discontinuation [7, 16]. For these two reasons
several authors have suggested that Finasteride
administration should be re-evaluated [46].
Therapeutic window and therapeutic opportunity of
Finasteride
The `therapeutic window` typically refers to the
pharmacological evaluation of a drug (in terms of
optimal biological dose/ time) so as to produce
optimal efficacy while remaining in the range of
acceptable toxicity/ adverse effects. When the
therapeutic effect is insignificant and/ or toxicity
(adverse effects) becomes unacceptable, the value
of the drug becomes questionable [32]. In the case of
Finasteride, preliminary data on patient complaints
during the post-market period suggested that adverse
effects were occurring more frequently than initially
assumed, with greater severity and persistence,
sometimes indefinitely even after the treatment was

terminated [5, 14]. For these reasons, the therapeutic
window of Finasteride appeared to warrant reevaluation (a relatively difficult process through the
classical tools) [46].
The “therapeutic opportunity” is generally applied
to preliminary investigations designed to evaluate
the opportunity of a drug for certain diseases/
patients [33]. In the case of Finasteride, after its
initial use, a second perspective evolved based on
observations that severe and persistent adverse
effects were encountered only in select patients;
other patients reported no complaints with respect
to drug administration [7, 16]. As a consequence, the
second perspective maintained that the therapeutic
window was relatively safe for some patients
(reporting no adverse effects), and further, that the
therapeutic opportunity was actually the issue of
concern, and it therefore should be reconsidered for
the subgroup of patients susceptible to developing
severe adverse effects [24, 25]. But this process
implies the formulation of relevant criteria that
differentiate this highly susceptible subgroup of
patients from those less or non-susceptible. So far,
two potential criteria have been identified - hand
preference and sexual orientation - that can help
predict the severity and type of adverse effects in
men under treatment [24, 25]. To understand why
some men respond with severe adverse effects
while others do not present adverse effects requires
an understanding of the neurobiological system
supporting this dual response.
The neurobiological substrate responsible by
distribution of Finasteride side effects
Anatomically, the human brain is divided by the
median plane into two different (left and right)
hemibrains. Each cerebral event is processed usually
in only one hemibrain (identified as the dominant
hemibrain), the opposite hemibrain supporting only
the neurological connection between dominant
hemibrain and peripheral receptors/effectors [29].
This asymmetric functioning of the brain is known
as lateralization, being possible from a physiologic
perspective through intervention of different neuro662
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modulators that channel environmental information
towards either the left or the right hemibrain [18,
37]. Without such preferential channelling, the left
and right hemibrains could receive, process, and
elaborate two distinct responses (competitive or,
even more problematic, contradictory) to the same
external stimulus/information, an eventuality that
would be not only inefficient, but also counterproductive [29].
With respect to sexuality, oestrogens modulate
environmental inputs especially toward the left
hemibrain. As a consequence, women exposed
prenatally to the synthetic oestrogen diethylstilbestrol are more likely to be left handed for
writing during development [41]. By the same
rationale, administration of antioestrogens such as
Tamoxifen induces sexual impairments especially
in left handed men [2, 26]. At the other end of the
spectrum, androgens channel the same environmental
information/inputs toward the contralateral/right
hemibrain [9]. In this respect, administration of
Finasteride or Bicalutamide induces sexual dysfunction
predominantly in right handed men [23, 27]. During
puberty, cortical maturation entails especially the left
hemibrain in human males, while in human females
this maturation involves predominantly the right
hemibrain [28, 36].
Regarding the lateralized action of pheromones, in
heterosexual men (sensitive to female pheromones)
the process of sexual activation involves especially
the right hemibrain (right hippocampus, right parahippocampal gyrus, etc.). In contrast, in homosexual
men (sensitive to male pheromones) the process of
sexual activation implies predominantly the left
hemibrain (the left angular gyrus, left caudate
nucleus, etc.) [11]. In support of this lateralized
process, heterosexual men and homosexual women
(lesbians) present a rightward volumetric cerebral
asymmetry (their connections being more widespread
from the right amygdala), while homosexual men
and heterosexual women display more widespread
connections from the left amygdala [38]. In
addition, empirical evidence indicates that homosexual
and heterosexual men are different regarding the
sizes/volume of hypothalamic nuclei [20].
Finasteride side effects according to lateralized
process of the brain
Returning to Finasteride administration in men,
sexual side effects are directly linked to decreasing
levels of DHTT. But the action of DHTT is strongly
related (through the right hemibrain) to a right
handed preference and female sexual pheromones/
heterosexual orientation. As a consequence, it is not
surprising that sexual side effects of Finasteride are
correlated with hand preference and sexual orientation.
In other words, hand preference and sexual
orientation could be used (prior to the treatment) as
possible eligibility criteria for selecting patients

having a low risk for developing sexual side effects
to 5α-reductase inhibitors like Finasteride.
Similar to sexual dysfunctions, psychological/cognitive
impairments resulting from Finasteride administration
are also directly related to lateralization processes in
the brain. Specifically, existing interrelations between
cognition and sexuality [29] can be highlighted
through several poignant examples. For example,
depression is closely related to estrogenic action,
being more frequently encountered in women than
men [34]. In addition, the incidence of depression
(associated with an inter-hemispheric imbalance) is
higher in left handed persons who present a
hyperactive right-hemisphere, due perhaps to an
inadequate or, alternatively, excessive activation of the
left hemibrain under estrogenic neuromodulation [6].
We limited the discussion above to the depressive
and sexual side effects of Finasteride, ones that are
sometimes severe and among those encountered more
frequently (being interrelated through lateralization
process of the brain). These processes may set up a
vicious neuro-endocrine cycle, with each (depressive
and sexual side effects) maintaining or intensifying
the other, and sometimes can persist indefinitely
after Finasteride cessation [36]. Beyond these
effects, Finasteride can also induce other adverse
effects that are related either to the direct presence
and action of the drug (pruritus, rash, urticaria,
gingival hypertrophy, etc.), or to other mechanisms
that are not hormonally mediated. As an example,
Finasteride administration may affect tolerance to
ethanol (through GABAA receptors), with many
former users of finasteride reporting decreased
tolerance and disturbing effects from alcohol
consumption (leading some men to stop drinking
entirely) [13, 46]. Other studies show that Finasteride
blocks the effects of dopamine receptors in the
nucleus accumbens, having thus a therapeutic
potential for certain neuropsychiatric disorders like
schizophrenia [42].
Summarizing, the therapeutic approach of male
androgenic alopecia and benign prostatic hyperplasia with Finasteride presented four successive
phases. The initial period was represented by approval
and introduction of the drug into clinical practice.
The enthusiasm generated and sustained by initial
therapeutic results was followed by a second, early
post-market period of patient complaints of increased,
more severe, and even irreversible adverse effects
that continued even after Finasteride cessation [46].
The third phase involved identifying of alternative or
personalized therapeutic solutions for male
androgenic alopecia and benign prostatic hyperplasia,
with fewer side effects and eventually superior
therapeutic results [3, 35]. Thus, Dutasteride was
often used as a replacement for Finasteride in the
therapeutic approach of benign prostatic hyperplasia
[3], a trend that was extended to androgenic
663

FARMACIA, 2017, Vol. 65, 5
3.

alopecia as well [8, 45]. Finally, the last phase - the
one that is currently emerging - suggests that
Finasteride should be reconsidered as a therapeutic
approach of androgenic alopecia [36].

4.

Conclusions
In conclusion, Finasteride could be further retained as
a therapeutic approach of male androgenic alopecia,
based on three important reasons.
First, male androgenic alopecia and benign prostatic
hyperplasia are only partly supported by DHTT
(other factors being also involved) [43], and DHTT
has its own important physiological roles within the
body [12]. Consequently, it makes more sense
physiologically to suppress DHTT synthesis only
partially (as Finasteride does) rather than almost
completely (as Dutasteride does). However, to
increase the therapeutic effects of Finasteride, we
suggest that the synergistic actions of drug
combinations (Finasteride plus Minoxidil, for
example, for androgenic alopecia) [10] could
provide a more suitable resolution than maximizing
a single drug effect (e.g., severe suppression of
DHTT by replacing Finasteride with Dutasteride).
Second, even if Finasteride adverse effects are
more frequent or severe than initially assumed,
recent evidence suggests that such adverse effects
are (at least in part) predictable, meaning that
screening of patients on a priori criteria (according
to current and forthcoming criteria) could lead to a
better compliance by patients.
Finally, adverse effects induced by Finasteride are
still being documented and studied, a difficult task
given that neither mental or sexual functions (often
affected in tandem by Finasteride) on one hand, nor
postfinasteride syndrome on the other hand, have
been completely described. Understanding their
link will require additional investigations regarding
symptomatology and the optimal therapeutic approach
to address the adverse effects [5].
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